Pierre Kory, MD,, Gianfranco Umberto Meduri, MD, Joseph Varon, MD, Jose Iglesias, DO, and Paul E. Marik, MD

PMCID: PMC8088823 PMID: 34375047


After COVID-19 emerged on U.S shores, providers began reviewing the emerging basic science, translational, and clinical data to identify potentially effective treatment options. In addition, a multitude of both novel and repurposed therapeutic agents were used empirically and studied within clinical trials.

Keywords: COVID-19, ivermectin

More on: I-PREVENT

More on: COVID-19 | ivermectin